Focusing on current issues in Life Sciences, BioFIT 2016’s conference programme promises a varied and rich agenda, featuring the latest opinions on trending topics.
Supported by its prestigious Steering Committee, the sessions will focus on three themes:
• Showcasing best practices in collaborative research
• Highlighting key issues in licensing and tech transfer
• Discussing early stage innovation funding
Description will be available soon.
BEST PRACTICES IN COLLABORATIVE RESEARCH
The recent rising popularity of the open innovation model has led pharmas, biotechs and academia to consider this as a win-win opportunity. Many types of partnerships have been developed and tested to analyze their strengths and weaknesses and how they advance innovation. We will debate the potential of this exciting, emerging model in cross sector collaborations as a new driver for rapid market access.
” Recent developments such as mobile health devices and big data are transforming the way we translate medical advances into new medicines. This track highlights how academia and industry are taking a more open and networked collaboration approach to improve the quality and richness of biomedical research. ”
Corporate Vice-President, Global Research Networking, Boehringer Ingelheim (Germany)
- Could standardized conditions be implemented by default in collaboration contracts?
- How would these contract-types be applied to the life sciences sector
- How will they influence the deal-making process: will it be a challenge or an opportunity?
Session held on 1st December from 4.00pm to 5.00 pm
- Hear from industry and VC accelerators
- Testimony from 1-2 previously incubated/supported companies
Session held on 1st December from 9.30am to 11.00am
KEY ISSUES IN LICENSING AND TECH TRANSFER
While academia aims to highlight knowledge and innovation, industry’s goal is to leverage this expertise and bring it to market. However, when an innovation appears from academia as a spin off or as a transferred license, many IP, due diligence, management and financing challenges arise. This track will discuss the processes and models available and the consequences on translational research.
“Pharma and biotech are looking increasingly towards academia for open innovation, explorative research and early stage discovery. But is academia prepared? Are the appropriate models and mechanisms in place to professionalise licensing and facilitate technology transfer? What about spin-outs and start-ups? Are the initial terms reasonable or a kiss of death? This track will challenge the current status of academic – industry relations. “
Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (Germany)
Experts on data protection, patents, trade secret, blockchain and smart contract will oppose, compare and discuss on the alternative and complementary ways to protect IP in Life Sciences
- Some researchers can become successful entrepreneurs, but often, an external CEO is brought into the company
- Are there successful models or mechanisms to help CEOs to create a wining scientific team?
- The importance/ role of the CEO to lead the company and face market and business challenges
Session held on 30th November from 2.30 pm to 4.00pm
- How does a university decide to what extent it gets involved with a spin-off?
- How do universities handle IP transfer and POC funding?
- How should we separate the responsibilities of business and university employees?
Session held on 1st December from 11.30am to 1.00pm
- How should TTOs choose between out licensing the IP, creating a spinoff or a contract-based R&D collaboration?
- What translation efforts don't fit into this classical TTO model?
Session held on 1st December from 2.30pm to 4.00 pm
EARLY STAGE INNOVATION: IDENTIFY THE RIGHT SOURCES of FUNDING
In a difficult economic climate, in which investors prefer to fund later stage companies, finding financial resources to progress your early stage project is challenging. In this track, we will discuss how VCs assess risk, non-traditional funding mechanisms available to finance early stage innovation and what a young biotech should do in order to attract investors.
“It is critical to find funding for early stage innovation and it is challenging to know what sources are available. Funding in the future will most certainly evolve. What will the trends be? It is therefore important to hear about inspirational ideas regarding different solutions in the US and Europe.”
Vice President Operations, Karolinska Development (Sweden)
- New trends are being seen as European academic research centres start to invest in better supporting early stage projects (from the pre-maturation phase to the potential creation of an academic start-up)
- New models such as pharma funds are being developed in partnership with universities in order to finance POC projects (e.g. the recent Apollo Therapeutic Funds)
Session held on 30th November from 9.30 am to 11.00 am
- Bio entrepreneur testimonials about their initial expectations and lessons learned
- Challenges encountered in the first years and how they overcame them
- The impact of external influence ( TTOs, incubators, etc.) on the evolution of the company
Session held on 30th November from 4.45pm to 6.30pm
- How former successful entrepreneurs stay active in the life sciences industry? How can they contribute to the growth of young companies? Advice or/and capital?
- How to attract the attention of experienced entrepreneurs?
Session held on 30th November from 4.45pm to 6.30pm
- Many initiatives are being seen at national levels in Europe to improve seed capital access, but does this exist at a European level?
- How to support the creation of a European seed capital market in order to finance research translation from academia?
Session held on 30th November from 2.30 pm to 4.00 pm
Description will soon be available
Session held on 1st December from 11.30 am to 1.00 pm